Literature DB >> 19361585

Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells.

Nikolas H Kazmers1, Sophia A Ma, Tomohiko Yoshida, Paula H Stern.   

Abstract

Cytoskeletal elements are critical for cell morphology and signal transduction, and are involved in many cellular processes including motility, intracellular transport, and differentiation. Small GTP-binding proteins (G proteins) of the Ras family, such as RhoA, influence various elements of the cytoskeleton. RhoA stabilizes the actin cytoskeleton and promotes formation of focal adhesions. We found previously that RhoA is expressed in osteoblastic cells and is translocated to the plasma membrane and activated by PTH 1-34 as well as by Nleu(8,18) Tyr(34) PTH 3-34 amide, a PTH analog that does not increase cAMP. We therefore investigated effects of manipulating RhoA on the actin cytoskeleton of osteoblastic MC3T3-E1 cells. Three inhibitors were used: 1) GGTI-2166, a geranylgeranyl transferase I inhibitor that prevents the isoprenylation and membrane translocation of RhoA, 2) Y-27632, a Rho kinase inhibitor, and 3) alendronate, a nitrogen (N)-containing bisphosphonate that reduces intracellular geranylgeranylpyrophosphate through inhibiting farnesyl pyrophosphate synthase. To increase RhoA activity, we used the geranylgeranyl group donor geranylgeraniol (GGOH), and a constitutively active RhoA. The F-actin cytoskeleton and focal adhesions (FA) were visualized with rhodamine-phalloidin and fluorescent anti-vinculin antibodies, respectively. Cells were imaged with confocal microscopy. Actin stress fiber density, edge actin bundle density, focal adhesion density, cellular area and circularity (a morphological descriptor relating area and perimeter) were quantified by a program developed with Matlab software. GGTI-2166, Y-27632, and alendronate reduced actin stress fibers, FA density, and FA size, but had no effect on edge actin bundle density, cellular area, or circularity. GGOH completely antagonized the effects of alendronate, but did not significantly affect responses to GGTI-2166 or Y-27632. Constitutively active RhoA antagonized the effects of alendronate and GGTI-2166, but not those of Y-27632. The effects of alendronate were also antagonized by Nleu(8,18) Tyr(34) PTH 3-34 amide, but not by PTH 1-34. The results indicate that RhoA is involved in the maintenance of stress fibers and focal adhesions in osteoblastic cells, that PTH can affect this pathway independently of cAMP, and that a N-containing bisphosphonate can affect the actin cytoskeleton and focal adhesions through actions on geranylgeranyl groups and potentially through RhoA. In view of the importance of the actin cytoskeleton, the findings constitute evidence that N-containing bisphosphonates, when they attain certain concentrations, have effects on osteoblasts that could influence bone remodeling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361585      PMCID: PMC2722510          DOI: 10.1016/j.bone.2009.03.675

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  What structures, besides adhesions, prevent spread cells from rounding up?

Authors:  M S Zand; G Albrecht-Buehler
Journal:  Cell Motil Cytoskeleton       Date:  1989

3.  Distinct effects of calcium- and cyclic AMP-enhancing factors on cytoskeletal synthesis and assembly in mouse osteoblastic cells.

Authors:  A Lomri; P J Marie
Journal:  Biochim Biophys Acta       Date:  1990-04-09

4.  Differential effects of parathyroid hormone and its analogues on cytosolic calcium ion and cAMP levels in cultured rat osteoblast-like cells.

Authors:  H J Donahue; M J Fryer; E F Eriksen; H Heath
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

5.  Changes in cytoskeletal proteins in response to parathyroid hormone and 1,25-dihydroxyvitamin D in human osteoblastic cells.

Authors:  A Lomri; P J Marie
Journal:  Bone Miner       Date:  1990-07

6.  Parathyroid hormone promotes the disassembly of cytoskeletal actin and myosin in cultured osteoblastic cells: mediation by cyclic AMP.

Authors:  J J Egan; G Gronowicz; G A Rodan
Journal:  J Cell Biochem       Date:  1991-01       Impact factor: 4.429

7.  Control of focal adhesion dynamics by material surface characteristics.

Authors:  Annette Diener; Barbara Nebe; Frank Lüthen; Petra Becker; Ulrich Beck; Hans Georg Neumann; Joachim Rychly
Journal:  Biomaterials       Date:  2005-02       Impact factor: 12.479

8.  Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells.

Authors:  Julie M Radeff; Zsolt Nagy; Paula H Stern
Journal:  J Bone Miner Res       Date:  2004-08-16       Impact factor: 6.741

9.  Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex.

Authors:  Dario Diviani; Liliane Abuin; Susanna Cotecchia; Laetitia Pansier
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

10.  Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.

Authors:  Jiazhi Sun; Junko Ohkanda; Domenico Coppola; Hang Yin; Mohit Kothare; Brian Busciglio; Andrew D Hamilton; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  11 in total

1.  Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Gα(12) or constitutively active RhoA.

Authors:  Jun Wang; Paula H Stern
Journal:  J Cell Biochem       Date:  2010-12-15       Impact factor: 4.429

2.  Parathyroid hormone regulation of hypoxia-inducible factor signaling in osteoblastic cells.

Authors:  Alice Wong; Gabriela G Loots; Clare E Yellowley; Andréa C Dosé; Damian C Genetos
Journal:  Bone       Date:  2015-07-04       Impact factor: 4.398

3.  Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells.

Authors:  J Wang; A Gilchrist; P H Stern
Journal:  Cell Signal       Date:  2010-10-19       Impact factor: 4.315

4.  The Load-Bearing Mechanosome Revisited.

Authors:  Joseph P Bidwell; Fredrick M Pavalko
Journal:  Clin Rev Bone Miner Metab       Date:  2010-11-11

Review 5.  Hypoxia-inducible factor signaling in vascular calcification in chronic kidney disease patients.

Authors:  Sidar Copur; Duygu Ucku; Mario Cozzolino; Mehmet Kanbay
Journal:  J Nephrol       Date:  2022-10-08       Impact factor: 4.393

6.  RhoA GTPase interacts with beta-catenin signaling in clinorotated osteoblasts.

Authors:  Qiaoqiao Wan; Eunhye Cho; Hiroki Yokota; Sungsoo Na
Journal:  J Bone Miner Metab       Date:  2013-03-26       Impact factor: 2.626

7.  Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition.

Authors:  Harikarn Mungpayabarn; Somying Patntirapong
Journal:  J Oral Biol Craniofac Res       Date:  2021-05-05

8.  Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells.

Authors:  Sara Rocío Chuguransky; Ana María Cortizo; Antonio Desmond McCarthy
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

9.  Rho kinase inhibitors stimulate the migration of human cultured osteoblastic cells by regulating actomyosin activity.

Authors:  Xuejiao Zhang; Cheng Li; Huiling Gao; Hiroaki Nabeka; Tetsuya Shimokawa; Hiroyuki Wakisaka; Seiji Matsuda; Naoto Kobayashi
Journal:  Cell Mol Biol Lett       Date:  2011-03-09       Impact factor: 5.787

10.  Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation.

Authors:  Luciana Bueno De Paiva; Vanessa Aline Bernusso; João Agostinho Machado-Neto; Fabiola Traina; Anne J Ridley; Sara Teresinha Olalla-Saad; Mariana Lazarini
Journal:  Small GTPases       Date:  2018-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.